Literature DB >> 26123279

Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans.

Daniel R Jacobson1, Alice A Alexander, Clement Tagoe, Joel N Buxbaum.   

Abstract

BACKGROUND: Transthyretin (TTR) V122I (rs76992529) is one of 111 variants caused by point mutations in the coding sequence of the human TTR gene that are associated with systemic amyloidosis. It results from a G to A transition at a CG dinucleotide in codon 142(122 of the mature protein) of the gene and has been described almost exclusively in people of African descent. Several series have reported allele frequencies from 0.015 to 0.020 in African-Americans.
OBJECTIVE: To define more accurately the frequency of the TTR V122I variant allele in the African-American population.
METHODS: DNA isolated from blood spots from 1688 New York State African-American newborns was genotyped for the TTR V122I allele. We also compiled new data from the Jackson Heart Study and previously unpublished data from the Dallas Heart Study, plus data from a San Diego "wellness study", providing 15 650 additional allelotypes to those already reported.
RESULTS: Among the New York newborns, the TTR V122I allele was present in 65/3376 alleles (allele prevalence 0.0193). The combined available data from all the non-selected African-American cohorts showed the TTR variant allele to be present in 451/26 062 alleles (allele prevalence of 0.0173), slightly but not significantly lower than our previously published estimates.
CONCLUSIONS: The allele prevalence for TTR V122I in African-Americans is 0.0173. Of African-Americans under age 65, 3.43% carry at least one copy of the variant amyloidogenic allele.

Entities:  

Keywords:  African–Americans; TTRV122I; amyloid cardiomyopathy; transthyretin

Mesh:

Substances:

Year:  2015        PMID: 26123279     DOI: 10.3109/13506129.2015.1051219

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  49 in total

1.  Identification of Transthyretin Cardiac Amyloidosis Using Serum Retinol-Binding Protein 4 and a Clinical Prediction Model.

Authors:  Marios Arvanitis; Clarissa M Koch; Gloria G Chan; Celia Torres-Arancivia; Michael P LaValley; Daniel R Jacobson; John L Berk; Lawreen H Connors; Frederick L Ruberg
Journal:  JAMA Cardiol       Date:  2017-03-01       Impact factor: 14.676

Review 2.  Cardiac amyloidosis: An update on pathophysiology, diagnosis, and treatment.

Authors:  Omar K Siddiqi; Frederick L Ruberg
Journal:  Trends Cardiovasc Med       Date:  2017-07-13       Impact factor: 6.677

3.  Epidemiology of Cardiac Amyloidosis-Associated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States.

Authors:  Lauren G Gilstrap; Francesca Dominici; Yun Wang; M Samir El-Sady; Amitoj Singh; Marcelo F Di Carli; Rodney H Falk; Sharmila Dorbala
Journal:  Circ Heart Fail       Date:  2019-06-07       Impact factor: 8.790

4.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.

Authors:  Sharmila Dorbala; Yukio Ando; Sabahat Bokhari; Angela Dispenzieri; Rodney H Falk; Victor A Ferrari; Marianna Fontana; Olivier Gheysens; Julian D Gillmore; Andor W J M Glaudemans; Mazen A Hanna; Bouke P C Hazenberg; Arnt V Kristen; Raymond Y Kwong; Mathew S Maurer; Giampaolo Merlini; Edward J Miller; James C Moon; Venkatesh L Murthy; C Cristina Quarta; Claudio Rapezzi; Frederick L Ruberg; Sanjiv J Shah; Riemer H J A Slart; Hein J Verberne; Jamieson M Bourque
Journal:  J Nucl Cardiol       Date:  2019-12       Impact factor: 5.952

Review 5.  Transthyretin Cardiac Amyloidosis in Black Americans.

Authors:  Keyur B Shah; Anit K Mankad; Adam Castano; Olakunle O Akinboboye; Phillip B Duncan; Icilma V Fergus; Mathew S Maurer
Journal:  Circ Heart Fail       Date:  2016-06       Impact factor: 8.790

Review 6.  Transthyretin Cardiac Amyloidosis.

Authors:  Anit K Mankad; Keyur B Shah
Journal:  Curr Cardiol Rep       Date:  2017-08-24       Impact factor: 2.931

Review 7.  Transthyretin Cardiac Amyloidosis in Older Americans.

Authors:  Danielle L Brunjes; Adam Castano; Autumn Clemons; Jonah Rubin; Mathew S Maurer
Journal:  J Card Fail       Date:  2016-10-18       Impact factor: 5.712

Review 8.  Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis.

Authors:  Mathew S Maurer; Perry Elliott; Raymond Comenzo; Marc Semigran; Claudio Rapezzi
Journal:  Circulation       Date:  2017-04-04       Impact factor: 29.690

Review 9.  Wild-Type Transthyretin Cardiac Amyloidosis: Novel Insights From Advanced Imaging.

Authors:  David L Narotsky; Adam Castano; Jonathan W Weinsaft; Sabahat Bokhari; Mathew S Maurer
Journal:  Can J Cardiol       Date:  2016-05-13       Impact factor: 5.223

10.  Prevalence of mutant ATTR cardiac amyloidosis in elderly African Americans with heart failure.

Authors:  Marios Arvanitis; Gloria G Chan; Daniel R Jacobson; John L Berk; Lawreen H Connors; Frederick L Ruberg
Journal:  Amyloid       Date:  2017-10-20       Impact factor: 7.141

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.